Venmax Drugs & Pharmaceuticals Ltd Share Price
Last Updated Date: 17 Sept 2026
₹13.60
-0.75 (-5.23%)
As of 18 Sept 2026, Venmax Drugs & Pharmaceuticals Ltd share price is ₹13.60. The stock opened at ₹13.60 and had closed at ₹14.35 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹13.52 and a high of ₹31.49. In terms of performance, Venmax Drugs & Pharmaceuticals Ltd share price has decreased by 42.25% over the past six months and has decreased by 45.64% over the last year.
Venmax Drugs Stock Price Chart
Venmax Drugs & Pharmaceuticals Ltd Overview
Market cap₹21 Crs
Volume10,479
Prev. Close₹14.35
Year range₹13.52 - ₹31.49
ISININE154G01022
About Venmax Drugs
Venmax Drugs & Pharmaceuticals is engaged in the business of pharmaceutical products, drug intermediaries and API’s
Venmax Drugs & Pharmaceuticals Ltd Historical Performance
1 Month Return-12.82%
6 Month Return-41.40%
3 Year Return-
3 Month Return-31.96%
1 Year Return-42.07%
5 Year Return-
Venmax Drugs & Pharmaceuticals Ltd Fundamentals
ROCE(TTM)2.03%
P/E Ratio (TTM)75.53
P/B Ratio1.00
Debt to Equity0.01
ROE1.87%
EPS (TTM)0.19
Dividend Yield0.00%
Book Value14.37
Profit Margin3.01%
Operating Margin1.61%
Venmax Drugs & Pharmaceuticals Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 8.18 | 1.86 | 0.20 | 0.42 | 1.98 |
| EBITDA | 0.28 | - | 0.10 | 0.24 | 1.86 |
| Net Profit | 0.25 | -0.01 | 0.06 | 0.23 | 1.85 |
| EPS | 0.21 | -0.02 | 0.12 | 0.43 | 3.52 |
Venmax Drugs & Pharmaceuticals Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 13.60 |
| Resistance 1 (R1) | 15.65 |
| Pivot Point | 14.90 |
Venmax Drugs & Pharmaceuticals Ltd Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| Sadhanala Venkata Rao | Managing Director |
| Swapneswar Mishra | Non Executive Independent Director |
| D. Rakesh Reddy | Non Executive Independent Director |
Venmax Drugs & Pharmaceuticals Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,857.30+0.21% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,327.00+1.85% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,818.50+0.12% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Venmax Drugs & Pharmaceuticals Ltd today is ₹13.60 on NSE and ₹13.60 on BSE.
- The 52-week high of Venmax Drugs & Pharmaceuticals Ltd is ₹31.49, while the 52-week low is ₹13.52.
- The current market capitalisation of Venmax Drugs & Pharmaceuticals Ltd is approximately ₹21 crore.
- The P/E (Price-to-Earnings) ratio of Venmax Drugs & Pharmaceuticals Ltd is 75.53. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Venmax Drugs & Pharmaceuticals Ltd is 1.00. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Venmax Drugs & Pharmaceuticals Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for Venmax Drugs on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Venmax Drugs & Pharmaceuticals Ltd has delivered a return of approximately N/A. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Venmax Drugs & Pharmaceuticals Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 10.46% promoters, 0.00% FIIs, 0.00% DIIs, and 74.34% public shareholders.
Download TradeMobi App
- Real-Time Market Data
- Advanced Trading Tools
- Expert-Backed Research
